Lyophilisation: difference between revisions
Diff·revision 54 → 55·01:10, 26 Aug 2025
Difference between revision 54 and revision 55 of Lyophilisation. 4 lines changed; the page grew by 982 bytes.
| Revision 54 — 11:01, 15 Aug 2025 BiosimilarBoaz (talk) move unsourced paragraph to talk 25,393 bytes +614 | Revision 55 — 01:10, 26 Aug 2025 SPPS_Sorrel (talk) expand §Cake attributes and their interpretation 26,375 bytes +982 | ||
|---|---|---|---|
| 151 | This is the basis for the common practice of shipping lyophilised research peptides at ambient temperature without refrigeration, and for manufacturers' statements that a lyophilised product tolerates transient warming. It is not a licence to disregard temperature entirely. The glass transition temperature of a dry peptide-sucrose matrix may be only 40–70 °C; a parcel left in a vehicle in summer can plausibly approach that range, and above it the matrix devitrifies and mobility rises sharply. Moisture ingress through a compromised seal has the same effect, because water plasticises the glass and lowers its transition temperature by tens of degrees.{{r|chang2009}} | 151 | This is the basis for the common practice of shipping lyophilised research peptides at ambient temperature without refrigeration, and for manufacturers' statements that a lyophilised product tolerates transient warming. It is not a licence to disregard temperature entirely. The glass transition temperature of a dry peptide-sucrose matrix may be only 40–70 °C; a parcel left in a vehicle in summer can plausibly approach that range, and above it the matrix devitrifies and mobility rises sharply. Moisture ingress through a compromised seal has the same effect, because water plasticises the glass and lowers its transition temperature by tens of degrees.{{r|chang2009}} |
| 152 | 152 | ||
| + | 153 | The evidence available for any particular unregulated product is usually nil. A manufacturer's stability programme conducted under [[Cold chain|cold-chain]] and ICH conditions produces data that support a labelled storage statement; material distributed without such a programme carries a storage recommendation that is, at best, an inference from the behaviour of similar compounds.{{r|ich_q1a}} Community-collated observations of material that appeared to perform normally after warm transit exist but are self-reported, unblinded, and without pre-excursion analytical baselines, and cannot establish the absence of degradation.{{r|ppcommunity}} | |
| + | 154 | ||
| 153 | == References == | 155 | == References == |
| 154 | {{reflist}} | 156 | {{reflist}} |
| ⋮ | ⋮ | ||
| 165 | <ref name="usp1207">United States Pharmacopeia, General Chapter <1207>, "Package Integrity Evaluation — Sterile Products". USP–NF, current revision.</ref> | 167 | <ref name="usp1207">United States Pharmacopeia, General Chapter <1207>, "Package Integrity Evaluation — Sterile Products". USP–NF, current revision.</ref> |
| 166 | <ref name="iso8362_5">ISO 8362-5:2016, ''Injection containers and accessories — Part 5: Freeze drying closures for injection vials''. International Organization for Standardization.</ref> | 168 | <ref name="iso8362_5">ISO 8362-5:2016, ''Injection containers and accessories — Part 5: Freeze drying closures for injection vials''. International Organization for Standardization.</ref> |
| + | 169 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | |
| + | 170 | <ref name="ppcommunity">PeptidePedia community handling-report tally, 2026 (self-reported, unblinded, no pre-exposure baselines; weak evidence — see [[Project:Sourcing_guidelines]]).</ref> | |
| 167 | 171 | ||
| 168 | == Further reading == | 172 | == Further reading == |